In a large population-based cohort, we show not all heterozygous APOEɛ4 carriers are at increased risk for Alzheimer’s disease (AD); a significantly higher AD proportion was only found for ɛ3/ɛ4, not ɛ2/ɛ4. Among ɛ3/ɛ4 carriers (24% in the cohort), the AD proportion differed considerably by polygenic risk score (PRS). In particular, the AD proportion was lower than the entire cohort for subjects in the bottom 20-percentile PRS and was higher than that of homozygous ɛ4 carriers for subjects at the top 5th-percentile PRS. Family history was no longer a significant predictor of AD risk after adjusting APOE and PRS.
2022 Alzheimer’s disease facts and figures. Alzheimers Dement18, 700–789.
2.
GatzM, ReynoldsCA, FratiglioniL, JohanssonB, MortimerJA, BergS, FiskeA, PedersenNL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry63, 168–174.
3.
CuyversE, SleegersK (2016) Genetic variations underlying Alzheimer’s disease: Evidence from genome-wide association studies and beyond. Lancet Neurol15, 857–868.
4.
GoldmanJS, HahnSE, CataniaJW, LaRusse-EckertS, ButsonMB, RumbaughM, StreckerMN, RobertsJS, BurkeW, MayeuxR, BirdT; American College of Medical Genetics and the National Society of Genetic Counselors (2011) Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med13, 597–605.
5.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
MarsN, LindbohmJV, Della Briotta ParoloP, WidenE, KaprioJ, PalotieA, FinnGen, RipattiS (2022) Systematic comparison of family history and polygenic risk across 24 common diseases. Am J Hum Genet109, 2152–2162.
8.
LiuCC, LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
9.
GoldmanJS, HahnSE, CataniaJW, LaRusse-EckertS, ButsonMB, RumbaughM, StreckerMN, RobertsJS, BurkeW, MayeuxR, BirdT (2019) ADDENDUM: Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med21, 2404.
10.
van der LeeSJ, WoltersFJ, IkramMK, HofmanA, IkramMA, AminN, van DuijnCM (2018) The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: A community-based cohort study. Lancet Neurol17, 434–444.
11.
de RojasI, Moreno-GrauS, TesiN, Grenier-BoleyB, AndradeV, JansenIE, PedersenNL, StringaN, ZettergrenA, HernandezI, et al. (2021) Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nat Commun12, 3417.
12.
BycroftC, FreemanC, PetkovaD, BandG, ElliottLT, SharpK, MotyerA, VukcevicD, DelaneauO, O’ConnellJ, CortesA, WelshS, YoungA, EffinghamM, McVeanG, LeslieS, AllenN, DonnellyP, MarchiniJ (2018) The UK Biobank resource with deep phenotyping and genomic data. Nature562, 203–209.
13.
LumsdenAL, MulugetaA, ZhouA, HypponenE (2020) Apolipoprotein E (APOE) genotype-associated disease risks: A phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine59, 102954.
14.
LambertSA, GilL, JuppS, RitchieSC, XuY, BunielloA, McMahonA, AbrahamG, ChapmanM, ParkinsonH, DaneshJ, MacArthurJAL, InouyeM (2021) The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat Genet53, 420–425.
15.
KheraAV, ChaffinM, ZekavatSM, CollinsRL, RoselliC, NatarajanP, LichtmanJH, D’OnofrioG, MatteraJ, DreyerR, SpertusJA, TaylorKD, PsatyBM, RichSS, PostW, GuptaN, GabrielS, LanderE, Ida ChenYD, TalkowskiME, RotterJI, KrumholzHM, KathiresanS (2019) Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. Circulation139, 1593–1602.
16.
LangloisCM, BradburyA, WoodEM, RobertsJS, KimSYH, RiviereME, LiuF, ReimanEM, TariotPN, KarlawishJ, LangbaumJB (2019) Alzheimer’s Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement (N Y)5, 705–716.
17.
GreenRC, RobertsJS, CupplesLA, RelkinNR, WhitehousePJ, BrownT, EckertSL, ButsonM, SadovnickAD, QuaidKA, ChenC, Cook-DeeganR, FarrerLA, REVEAL Study Group (2009) Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med361, 245–254.
18.
WoltersFJ, van der LeeSJ, KoudstaalPJ, van DuijnCM, HofmanA, IkramMK, VernooijMW, IkramMA (2017) Parental family history of dementia in relation to subclinical brain disease and dementia risk. Neurology88, 1642–1649.
